Articles with public access mandates - Gavin StuartLearn more
Not available anywhere: 3
Clinical trials in recurrent ovarian cancer
M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ...
International Journal of Gynecologic Cancer 21 (4), 2011
Mandates: US National Institutes of Health
First-line therapy in ovarian cancer trials
T Thigpen, J McAlpine, P DiSaia, K Fujiwara, W Hoskins, G Kristensen, ...
International Journal of Gynecologic Cancer 21 (4), 2011
Mandates: US National Institutes of Health
Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?: An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 …
L Verleye, PB Ottevanger, GB Kristensen, T Ehlen, N Johnson, ...
European Journal of Cancer 47 (1), 57-64, 2011
Mandates: US National Institutes of Health
Available somewhere: 25
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson, ...
New England Journal of Medicine 363 (10), 943-953, 2010
Mandates: US National Institutes of Health
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ...
New England Journal of Medicine 372 (8), 711-723, 2015
Mandates: Cancer Research UK
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer
GCE Stuart, H Kitchener, M Bacon, C Marth, T Thigpen, E Trimble
Int J Gynecol Cancer 21 (4), 750-755, 2011
Mandates: US National Institutes of Health
A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer
LA Brotto, Y Erskine, M Carey, T Ehlen, S Finlayson, M Heywood, J Kwon, ...
Gynecologic oncology 125 (2), 320-325, 2012
Mandates: Canadian Institutes of Health Research
Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial
GS Ogilvie, D van Niekerk, M Krajden, LW Smith, D Cook, L Gondara, ...
Jama 320 (1), 43-52, 2018
Mandates: Canadian Institutes of Health Research
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ...
The Lancet Oncology 19 (12), 1680-1687, 2018
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease
MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ...
Annals of Oncology 28 (4), 727-732, 2017
Mandates: US National Institutes of Health
A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)
GS Ogilvie, DJ van Niekerk, M Krajden, RE Martin, TG Ehlen, K Ceballos, ...
BMC cancer 10, 1-10, 2010
Mandates: Canadian Institutes of Health Research
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
I Vergote, A Gonzalez-Martin, D Lorusso, C Gourley, MR Mirza, JE Kurtz, ...
The Lancet Oncology 23 (8), e374-e384, 2022
Mandates: US National Institutes of Health, Health Research Board, Ireland, National …
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, C Marth, I McNeish, KN Moore, A Poveda, ...
Annals of Oncology 28 (4), 702-710, 2017
Mandates: UK Medical Research Council
The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus
E McClymont, M Lee, J Raboud, F Coutlée, S Walmsley, N Lipsky, ...
Clinical infectious diseases 68 (5), 788-794, 2019
Mandates: Canadian Institutes of Health Research
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours
AF Leary, M Quinn, K Fujiwara, RL Coleman, E Kohn, T Sugiyama, ...
Annals of Oncology 28 (4), 718-726, 2017
Mandates: US National Institutes of Health, Cancer Research UK
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
MA Bookman, A Okamoto, G Stuart, N Yanaihara, D Aoki, M Bacon, ...
Annals of Oncology 28, viii30-viii35, 2017
Mandates: US National Institutes of Health
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
JA Ledermann, C Marth, MS Carey, M Birrer, DDL Bowtell, S Kaye, ...
International Journal of Gynecologic Cancer 21 (4), 2011
Mandates: US National Institutes of Health
The Cervix Cancer Research Network: a global outreach effort on behalf of the Gynecologic Cancer Intergroup
DK Gaffney, G Suneja, SY Ryu, M McCormick, M Plante, L Mileshkin, ...
International journal of radiation oncology, biology, physics 92 (3), 506-508, 2015
Mandates: US National Institutes of Health
Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial
AJ Coldman, L Gondara, LW Smith, D van Niekerk, K Ceballos, M Krajden, ...
British journal of cancer 115 (12), 1487-1494, 2016
Mandates: Canadian Institutes of Health Research
Assessing 10-year safety of a single negative HPV test for cervical cancer screening: evidence from FOCAL-DECADE cohort
A Gottschlich, D van Niekerk, LW Smith, L Gondara, J Melnikow, DA Cook, ...
Cancer Epidemiology, Biomarkers & Prevention 30 (1), 22-29, 2021
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program